Veterinarians can now legally obtain a compounded drug for managing feline infectious peritonitis (FIP), a fatal and difficult-to-detect disease caused by feline coronavirus (FCoV).
Made available through an exclusive partnership between Bova Group and Stokes Pharmacy, the compounded medication, GS-441524, is now available in a quad-scored, 50-mg tuna-flavored tablet, with dosages that address FIP diagnoses, including:
- With effusions but without any ocular or neurological involvement (wet FIP)
- No effusion and without ocular or neurological signs (dry FIP)
- With ocular signs (no neurological involvement)
- With neurological signs
Prior to the availability of this medication, U.S. veterinarians did not have access to oral FIP treatment and resorted to treat the virus with prednisolone, interferon, and polyprenyl immunostimulant. In an announcement by the U.S. Food & Drug Administration (FDA), the agency states it “does not intend to enforce new animal drug approval requirements for products compounded from GS-441524, when prescribed by a veterinarian for a specific cat patient for the treatment of [FIP] under the conditions listed in Guidance for Industry (GFI) #256 Compounding Animal Drugs from Bulk Drug Substances.”
For more information, visit the Stokes Pharmacy website.